CLAIMS

1. A pharmaceutical kit for the treatment of retinitis pigmentosa containing the enzymes glutathione peroxidase (Enzyme A), prolidase (Enzyme B), glucose-6-phosphate dehydrogenase (Enzyme C) and, optionally, aldose reductase (Enzyme D) in aliquot parts and interactive quantities appropriate for administering:

a) Enzyme A at a concentration comprised between 0.03 and 0.05 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye;

b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration of 5 to 7 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye;

c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration of 7 to 9 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye.

d) Enzyme D, starting from the month following the last administration of Enzyme C, at a concentration of 5 to 7 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye.

2. A kit in accordance with Claim 1, wherein the concentration of Enzyme A is 0.04 U.I in 0.4 ml of physiological solution, the concentration of Enzyme B is 6.67 U.I. in 0.4 ml of physiological solution and the

concentration of Enzyme C is 8 U.I in 0.4 ml of physiological solution, the concentration of optional Enzyme D being equal to 8 U.I. in 0.4 ml of physiological solution.

3. A kit in accordance with Claim 1 or Claim 2, wherein said kit comprises said enzymes in lyophilised form, in quantities sufficient for at least one series of administrations of from a) to c) and, optionally, also d), subdivided into aliquot parts containing - for each enzyme - a quantity of enzyme sufficient for the constitution of said aliquot parts.

4. A kit in accordance with any one of Claims 1 to 3, wherein said kit comprises said enzymes in lyophilised form subdivided into one or more aliquot parts, each containing from 0.04 U.I. to 0.72 U.I of Enzyme A, from 0.67 to 120 U.I of Enzyme B, from 8 to 144 U.I of Enzyme C and, optionally, from 8 to 144 U.I of Enzyme D, and, optionally, three or more aliquot parts of physiological solution of from 0.4 to 7.2 ml each.

5. Use of the enzymes glutathione peroxidase (Enzyme A), prolidase (Enzyme B), glucose-6-phosphate dehydrogenase (Enzyme C) and, optionally, aldose reductase (Enzyme D) for the preparation of a pharmaceutical composition in kit form for the treatment of retinitis pigmentosa by means of injection into the retrobulbar tissue, said kit containing said enzymes in aliquot parts and interactive quantities appropriate for administering:

a) Enzyme A at a concentration comprised between 0.03 and 0.05 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye;

b) Enzyme B, starting from the month following the last administration of Enzyme A, at a

concentration of 5 to 7 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye;

c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration of 7 to 9 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye.

d) Enzyme D, starting from the month following the last administration of Enzyme C, at a concentration of 5 to 7 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye.

6. Use of the enzymes in accordance with Claim 6, wherein concentration of Enzyme A is 0.04 U.I in 0.4 ml of physiological solution, the concentration of Enzyme B is 6.67 U.I. in 0.4 ml of physiological solution and the concentration of Enzyme C is 8 U.I in 0.4 ml of physiological solution, the concentration of optional Enzyme D being equal to 8 U.I. in 0.4 ml of phisiological solution.

7. Use of the enzymes in accordance with Claims 5 or 6, wherein said kit comprises said enzymes in lyophilised form, in quantities sufficient for at least one series of administrations of from a) to c) and, optionally, also d), subdivided into aliquot parts containing - for each enzyme - a quantity of enzyme sufficient for the constitution of said aliquot parts.

8. Use of the enzymes in accordance with any one of the preceding claims, wherein said kit comprises said enzymes

in lyophilised form subdivided into one or more aliquot parts, each containing from 0.04 U.I. to 0.72 U.I of Enzyme A, from 0.67 to 120 U.I of Enzyme B, from 8 to 144 U.I of Enzyme C and, optionally, from 8 to 144 U.I of Enzyme D, and, optionally, three or more aliquot parts of physiological solution of from 0.4 to 7.2 ml each.

9. A method for the treatment of retinitis pigmentosa that envisages the administration by means of injection into the retrobulbar tissue of:

a) Enzyme A at a concentration comprised between 0.03 and 0.05 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye;

b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration of 5 to 7 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye;

c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration of 7 to 9 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye;

d) optionally, Enzyme D, starting from the month following the last administration of Enzyme C, at a concentration of 5 to 7 U.I. in 0.4 ml of physiological solution for three consecutive days, at monthly intervals, for three months and for each eye.

10. A method in accordance with Claim 9, wherein the concentration of Enzyme A is 0.04 U.I in 0.4 ml of

physiological solution, the concentration of Enzyme B is 6.67 U.I. in 0.4 ml of physiological solution and the concentration of Enzyme C is 8 U.I in 0.4 ml of physiological solution, the concentration of optional Enzyme D being equal to 8 U.I. in 0.4 ml of physiological solution.